A Phase 1 interventional study of OCU-10-C-110 in neovascular age-related macular degeneration

Active, Not Recruiting Phase 1 NCT05904691

Study Description

A study to evaluate the safety and tolerability of a new investigational drug, OCU-10-C-110, for the treatment of neovascular age-related macular degeneration

Study Details

Registry ID:: NCT05904691
Conditions:: Neovascular Age-related Macular Degeneration (nAMD)
Phase:: Phase 1
Target Enrollment:: 24 participants
Start Date:: November 1, 2023
Age Range:: 50–999 years
Healthy Volunteers:: No

Study Locations (4 sites)

Raj K. Maturi, M.D., P.C.
Carmel, IndianaUnited States, United States
Strategic Clinical Research Group LLC
Willow Park, TexasUnited States, United States
Retina Research Institute of Texas
Abilene, TexasUnited States, United States
Strategic Clinical Research Group LLC
Abilene, TexasUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →